CD19 and acute myeloid leukemia: Other studies also showed the activation of FOXO3A, C/EBP-beta, Btk, LKB1, CD19 in AML as we have seen in the present study that FOXO3A and LKB1 peptides were highly activated in cluster-2 patients and C/EBP-beta, CD19, Btk were highly activated in cluster-1 patients which suggests importance of this approach to identify targeting therapies for individual patients [23–28].